---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-21-017355"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:44:24.747721+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precigen reports Phase 1 data: 50% AML ORR, 40% HPV ORR; cash $181.3M

## Summary
- 50% ORR (3/6) in relapsed/refractory AML at low dose levels of PRGN-3006 UltraCAR-T in Phase 1 lymphodepletion cohort.
- 40% ORR (2/5) and 60% DCR (3/5) in recurrent/metastatic HPV-associated cancer with PRGN-2009 AdenoVerse combination arm.
- PRGN-3006 and PRGN-3005 show no dose-limiting toxicities or neurotoxicity; durable expansion and persistence observed.
- Cash, equivalents, and investments totaled $181.3M at Sep 30, 2021; net cash used in ops $41.2M (9 months, vs $60.6M prior year).
- PRGN-3006 abstract selected for oral presentation at 63rd ASH Annual Meeting.

## SEC filing metadata
- accession: 0000950103-21-017355
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010321017355/0000950103-21-017355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010321017355/dp161305_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-21-017355
- JSON: https://secwatch.observer/filing/0000950103-21-017355.json
- Plain text: https://secwatch.observer/filing/0000950103-21-017355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.